TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28837405

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks up to 2 years or until disease progression or unacceptable toxicity
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (central review)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 27
Study: 28837430

Group type: EXPERIMENTAL
Intervention: Chronic critical illness patients
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Patients who developed chronic critical illness
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Independent predictors of chronic critical illness
Number of subjects: 135
Study: 28837885

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 12537

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12537
Study: 28838044

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation with vitamin-K antagonists or non-VKA oral anticoagulants
Number of subjects: 84

Group type: COMPARATOR
Intervention: Antiplatelet therapy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Chronic oral anticoagulation
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TAVI and SAVR (both interventions)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 84
Study: 28838858

Group type: EXPERIMENTAL
Intervention: Concurrent cartilage thickness change (Y2→Y4)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Preceding cartilage thickness loss (cMFTC)
Number of subjects: 777
Study: 28838886

Group type: EXPERIMENTAL
Intervention: iMOVE intervention with 10 telephone-based health coaching sessions, smartphone with data plan, supportive health tracking software, and a wearable step-counting device.
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: iMOVE intervention
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group receiving the 12-week physical activity program with weekly group sessions and an individualized, progressive, home-based exercise program.
Number of subjects: 107

Group type: COMPARATOR
Intervention: Both intervention and control groups
Number of subjects: 107
Study: 28838993

Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Low risk group (n=199)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Intermediate risk group (n=68)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: High risk group (n=42)
Number of subjects: 350
Study: 28840039

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV) with silicone oil endotamponade, performed in 93% of cases, simultaneous with phacoemulsification and IOL implantation in 86% of cases.
Number of subjects: 14
Study: 28840096

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28840147

Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg intramuscularly weekly for 8 weeks)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (saline intramuscularly weekly for 8 weeks)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 28840587

Group type: EXPERIMENTAL
Intervention: Biomedical shirt-based electrocardiography (ECG) monitoring using the Nuubo® ECG (nECG) system
Number of subjects: 220
Study: 28840775

Group type: COMPARATOR
Intervention: Perinatal Asphyxia (PA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypoxic-Ischaemic Encephalopathy (HIE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pathway analysis for HIE
Number of subjects: 0
Study: 28840919

Group type: EXPERIMENTAL
Intervention: Virtual visits with remote PD specialists
Number of subjects: 277
Study: 28841389

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Osimertinib 160 mg once daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Osimertinib across doses
Number of subjects: 60
Study: 28841495

Group type: EXPERIMENTAL
Intervention: Adverse Childhood Experience (ACE) score
Number of subjects: 457
Study: 28841677

Group type: EXPERIMENTAL
Intervention: TTT workshop
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Community activities delivered by trainees
Number of subjects: 32
Study: 28841744

Group type: EXPERIMENTAL
Intervention: IONIS-HTTRx (antisense oligonucleotide)
Number of subjects: 0
Study: 28841824

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg for 6 weeks
Number of subjects: 131
Study: 28841909

Group type: EXPERIMENTAL
Intervention: Standard DCF regimen (6 cycles)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Modified DCF regimen (8 cycles)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cisplatin and 5-fluorouracil (CF) regimen (standard option)
Number of subjects: 66
Study: 28842294

Group type: EXPERIMENTAL
Intervention: Preoperative intra-platelet serotonin (IP5-HT) levels >134ng/ml
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Preoperative intra-platelet serotonin (IP5-HT) levels <73ng/ml
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor treatment
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Preoperative intra-platelet serotonin (IP5-HT) levels
Number of subjects: 96
Study: 28842390

Group type: EXPERIMENTAL
Intervention: Exergames (VR intervention)
Number of subjects: 19
Study: 28842415

Group type: EXPERIMENTAL
Intervention: Threat condition (unpredictable shocks) during retrieval of altered images
Number of subjects: 0

Group type: COMPARATOR
Intervention: Safety condition (no shocks) during retrieval of altered images
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retrieval of altered items during threat
Number of subjects: 0
Study: 28842973

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor
Number of subjects: 446
Study: 28843382

Group type: EXPERIMENTAL
Intervention: Air infusion into saline during office hysteroscopy
Number of subjects: 0
Study: 28843918

Group type: EXPERIMENTAL
Intervention: Cariprazine 3-12 mg/d (mean 6.2 mg/d) for up to 16 weeks
Number of subjects: 402
Study: 28844037

Group type: EXPERIMENTAL
Intervention: Lateral angulation technique (LAT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Traditional angulation technique (TAT)
Number of subjects: 25
Study: 28844356

Group type: EXPERIMENTAL
Intervention: Pertubation with lignocaine
Number of subjects: 37
Study: 28844372

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160mg/d orally
Number of subjects: 214
Study: 28844410

Group type: EXPERIMENTAL
Intervention: PRI-724 (10mg/m and 40mg/m)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PRI-724 (160mg/m)
Number of subjects: 14
Study: 28844733

Group type: EXPERIMENTAL
Intervention: Intervention patients received brief clinician advice, video doctor message, health education booklet, and follow-up coaching sessions.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control patients received usual care and cancer screening information.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intervention patients
Number of subjects: 65
Study: 28845238

Group type: EXPERIMENTAL
Intervention: Auditory Training (AT) for 40 hours
Number of subjects: 56

Group type: COMPARATOR
Intervention: Computer Games (CG)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Baseline MMN in ESZ individuals
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Double-Deviant MMN
Number of subjects: 56
Study: 28845304

Group type: EXPERIMENTAL
Intervention: Double internal limiting membrane (ILM) insertion
Number of subjects: 9
Study: 28845508

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 41
Study: 28845608

Group type: EXPERIMENTAL
Intervention: Weight variability over 6-week period
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Weight variability over 12-week period
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Weight variability early in a weight loss program
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Weight variability over 6-month period in men
Number of subjects: 183
Study: 28846559

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) combined with daclatasvir with or without ribavirin (n = 10/n = 6)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) combined with ledipasvir with or without ribavirin (n = 2/n = 11)
Number of subjects: 29
Study: 28846801

Group type: EXPERIMENTAL
Intervention: Bipolar disorder with comorbid premenstrual dysphoric disorder (PMDD)
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Bipolar disorder with comorbid PMDD
Number of subjects: 1099
Study: 28846953

Group type: EXPERIMENTAL
Intervention: WT1 overexpression >350 copies after induction
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: WT1 overexpression >150 copies pre allo-HCT
Number of subjects: 255
Study: 28847194

Group type: EXPERIMENTAL
Intervention: CT-guided microwave ablation (MWA)
Number of subjects: 32
Study: 28847910

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 12
Study: 28847911

Group type: EXPERIMENTAL
Intervention: Hypertensive patients with HTN-LVH and low RI (n=15, 5.9%)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Hypertensive patients with HTN-LVH and normal RI (n=50; 19.5%)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Hypertensive patients without LVH (n=191; 74.6%)
Number of subjects: 266
Study: 28847998

Group type: EXPERIMENTAL
Intervention: Venetoclax (50-1200 mg, 800 mg in safety expansion) plus bortezomib and dexamethasone
Number of subjects: 66
Study: 28848011

Group type: COMPARATOR
Intervention: Ritonavir at 100 mg daily for 2 weeks, followed by DE 150 mg given 2 h before and simultaneously with ritonavir.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cobicistat at 150 mg daily for 2 weeks, followed by DE 150 mg given 2 h before and simultaneously with cobicistat.
Number of subjects: 0
Study: 28848465

Group type: EXPERIMENTAL
Intervention: 8-Session Mindfulness-Based Intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-Session Mindfulness-Based Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 28848654

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 28848667

Group type: EXPERIMENTAL
Intervention: Study drug (specific intervention not mentioned)
Number of subjects: 31
Study: 28848672

Group type: EXPERIMENTAL
Intervention: IT-139 (625 mg/m)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: IT-139 (various doses: 20, 40, 80, 160, 320, 420, 500, 625, 780 mg/m)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: IT-139
Number of subjects: 46
Study: 28848879

Group type: EXPERIMENTAL
Intervention: Twice-Daily Glycopyrrolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28848909

Group type: EXPERIMENTAL
Intervention: Alpha-1 proteinase inhibitor (A1PI)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 28850430

Group type: EXPERIMENTAL
Intervention: Locally orientated treatment for ACNES
Number of subjects: 50
Study: 28851109

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 321

Group type: COMPARATOR
Intervention: Sulphonylurea
Number of subjects: 321
Study: 28851316

Group type: EXPERIMENTAL
Intervention: ParvOryx (native parvovirus H-1) administered intravenously and intratumorally
Number of subjects: 7
Study: 28851348

Group type: EXPERIMENTAL
Intervention: Modified Environment and Policy Assessment and Observation (EPAO)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Modified EPAO
Number of subjects: 61
Study: 28851380

Group type: EXPERIMENTAL
Intervention: CD40L stimulation of lymph node cells
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: B cell ELISPOT
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hybridomas generated from lymph node cells after CD40L-stimulation
Number of subjects: 6
Study: 28851416

Group type: EXPERIMENTAL
Intervention: Class 1 GEP profile
Number of subjects: 322

Group type: COMPARATOR
Intervention: Class 2 GEP profile
Number of subjects: 322
Study: 28851415

Group type: EXPERIMENTAL
Intervention: Pre-chemotherapy IL-6 levels
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Pre-chemotherapy D-dimer levels
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Increased age
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Increased number of comorbidities
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Decreased physical function by ADL Scale
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Multivariate model including IL-6 and D-dimer
Number of subjects: 159
Study: 28851423

Group type: EXPERIMENTAL
Intervention: PARP inhibitor veliparib in combination with carboplatin (V-C)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard chemotherapy alone (Control)
Number of subjects: 116
Study: 28851447

Group type: EXPERIMENTAL
Intervention: Amnestic mild cognitive impairment (aMCI)
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: Non-amnestic mild cognitive impairment (naMCI)
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: Isolated subjective cognitive complaints (SCCs)
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2323

Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 2323
Study: 28851512

Group type: EXPERIMENTAL
Intervention: Velaglucerase alfa
Number of subjects: 43
Study: 28851731

Group type: EXPERIMENTAL
Intervention: Invasive physiological assessment for coronary stenosis
Number of subjects: 115
Study: 28851773

Group type: EXPERIMENTAL
Intervention: Fast-track care
Number of subjects: 1820

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 1820
Study: 28851774

Group type: EXPERIMENTAL
Intervention: Time Together intervention
Number of subjects: 0
Study: 28851781

Group type: EXPERIMENTAL
Intervention: Observational study design with document acquisition and abstraction and in-person interviews.
Number of subjects: 1000000
Study: 28851978

Group type: EXPERIMENTAL
Intervention: Therapy assessed by changes in SOFA score from admission (T1) to 48 hours later (T2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: SOFA score at admission (T1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: SOFA score at 48 hours (T2)
Number of subjects: 21
Study: 28852473

Group type: EXPERIMENTAL
Intervention: Intraoperative reverse Trendelenburg positioning (RTP)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Post-campaign 2015 cohort with increased RTP
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Audit-documented RTP during surgery in 2015
Number of subjects: 1500
Study: 28853310

Group type: EXPERIMENTAL
Intervention: Romidepsin
Number of subjects: 0
Study: 28853988

Group type: EXPERIMENTAL
Intervention: Healthier household food availability
Number of subjects: 2520

Group type: EXPERIMENTAL
Intervention: Higher log supermarket spending
Number of subjects: 2520

Group type: EXPERIMENTAL
Intervention: Healthier household food availability (females)
Number of subjects: 2520

Group type: EXPERIMENTAL
Intervention: Greater log supermarket spending (females)
Number of subjects: 2520
Study: 28854543

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine delivered i.v. by target-controlled infusion
Number of subjects: 18
Study: 28854909

Group type: EXPERIMENTAL
Intervention: Supplementation with one tablet of 100 mg feverfew, 100 mg coenzyme Q10 and 112.5 mg magnesium per day for 3 months.
Number of subjects: 68
Study: 28855148

Group type: EXPERIMENTAL
Intervention: Immediate ivermectin treatment with antiepilepsy drugs (AEDs)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Delayed ivermectin treatment (after 4 months) with antiepilepsy drugs (AEDs)
Number of subjects: 110
Study: 28855200

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) or Golimumab (GLM)
Number of subjects: 223
Study: 28855902

Group type: EXPERIMENTAL
Intervention: HBsAg with AS01
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: HBsAg with different Adjuvant Systems (AS)
Number of subjects: 291
Study: 28856009

Group type: EXPERIMENTAL
Intervention: High water intake (1.0 to 1.5 L/day increase)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Usual water intake (control group)
Number of subjects: 631
Study: 28856176

Group type: EXPERIMENTAL
Intervention: 8-week washout (WO) group
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 12-week washout (WO) group
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 16-week washout (WO) group
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Higher T2 lesion volume (LV) at baseline
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Faster decline in natalizumab RO
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Longer washout period
Number of subjects: 142
Study: 28856631

Group type: EXPERIMENTAL
Intervention: Entropy and SPI-guided general anaesthesia (ESPI Group, N=37)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard haemodynamic monitoring (STDR Group, N=35)
Number of subjects: 72
Study: 28856960

Group type: EXPERIMENTAL
Intervention: Task Oriented Training and Evaluation at Home (TOTE Home) program, 30 sessions of 1 hour each
Number of subjects: 4
Study: 28857778

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 901
Study: 28857822

Group type: EXPERIMENTAL
Intervention: Protease inhibitor-based antiretroviral therapy (ART)
Number of subjects: 103
Study: 28857936

Group type: EXPERIMENTAL
Intervention: Circumferential anal RFA using Barrx 60 RFA focal catheters, median duration of treatment 6.5 minutes (range 5-13 minutes).
Number of subjects: 10
Study: 28858441

Group type: EXPERIMENTAL
Intervention: THINC-integrated tool (THINC-it)
Number of subjects: 100
Study: 28858443

Group type: EXPERIMENTAL
Intervention: Citalopram monotherapy
Number of subjects: 2280
Study: 28858564

Group type: EXPERIMENTAL
Intervention: CT angiography with image processing algorithms
Number of subjects: 31
Study: 28858898

Group type: EXPERIMENTAL
Intervention: Wireless handheld ultrasound with pattern recognition software (Accuro)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Tuohy needle depth to epidural space
Number of subjects: 47
Study: 28859185

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin plus mini-hyper-CVD chemotherapy (1.8 to 1.3 mg/m2 for cycle 1 followed by 1.3 to 1.0 mg/m2 for subsequent cycles).
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin plus mini-hyper-CVD chemotherapy.
Number of subjects: 59
Study: 28859325

Group type: EXPERIMENTAL
Intervention: Near-remission (mean PGA 3.6, s.d. 1.9)
Number of subjects: 1588

Group type: COMPARATOR
Intervention: Non-remission
Number of subjects: 1588

Group type: COMPARATOR
Intervention: Remission
Number of subjects: 1588
Study: 28859622

Group type: EXPERIMENTAL
Intervention: Exposure group (positive for anti-HPA antibody)
Number of subjects: 55497

Group type: COMPARATOR
Intervention: Non-exposure group (negative for anti-HPA antibody)
Number of subjects: 55497
Study: 28859648

Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC) intervention including in-person outpatient palliative care consultation and telephonic nurse coach sessions with monthly calls.
Number of subjects: 61
Study: 28859794

Group type: EXPERIMENTAL
Intervention: Guideline-Based Primary Prevention Implantable Cardioverter-Defibrillator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Off-Guideline Primary Prevention Implantable Cardioverter-Defibrillator
Number of subjects: 0
Study: 28860107

Group type: EXPERIMENTAL
Intervention: Couples' HIV counseling and testing plus dyadic adherence counseling
Number of subjects: 330

Group type: COMPARATOR
Intervention: Individual HIV counseling and testing
Number of subjects: 330
Study: 28860229

Group type: EXPERIMENTAL
Intervention: Indicators of the appropriateness of oral anticoagulant prescriptions developed from hospital information systems.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Delphi consensus method for assessing utility and operational implementation of selected indicators.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cross-sectional study to assess the ability of indicators to detect inappropriate oral anticoagulant prescriptions.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tools for transferring indicators into other institutions.
Number of subjects: 80
Study: 28860342

Group type: EXPERIMENTAL
Intervention: CUDC-907 monotherapy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CUDC-907 with rituximab
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CUDC-907 in MYC-altered DLBCL patients
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CUDC-907 in MYC unaltered DLBCL patients
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CUDC-907 in patients with unknown MYC status
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CUDC-907 overall
Number of subjects: 37
Study: 28861121

Group type: EXPERIMENTAL
Intervention: Tacrolimus 3 mg daily for 24 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 28862132

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28862547

Group type: EXPERIMENTAL
Intervention: Interventional management (first RCT)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Preembolization as an adjunct to surgery or radiotherapy (second RCT)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Clinical judgment alone (registry)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Surgery (first RCT)
Number of subjects: 107
Study: 28862877

Group type: EXPERIMENTAL
Intervention: Mepolizumab (750 mg intravenous dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Segmental allergen challenge without mepolizumab
Number of subjects: 0
Study: 28862936

Group type: EXPERIMENTAL
Intervention: Carotid magnetic resonance imaging (CMRI) for detecting high-risk plaques (HRP)
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Maximum wall thickness measurement
Number of subjects: 1047
Study: 28862950

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic cycle training for 12 weeks
Number of subjects: 73
Study: 28862959

Group type: EXPERIMENTAL
Intervention: Perceval sutureless aortic valve bioprosthesis
Number of subjects: 47
Study: 28862963

Group type: EXPERIMENTAL
Intervention: Women with STEMI (delayed care)
Number of subjects: 6022

Group type: EXPERIMENTAL
Intervention: Patients with delays from symptom onset to hospital presentation of ≤1 hour
Number of subjects: 6022
Study: 28862970

Group type: EXPERIMENTAL
Intervention: Low FFR (≤0.80)
Number of subjects: 1024

Group type: COMPARATOR
Intervention: High FFR (>0.80)
Number of subjects: 1024
Study: 28862971

Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 15828

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15828